142 related articles for article (PubMed ID: 8349438)
1. Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancer.
Moore M; Maroun J; Robert F; Natale R; Neidhart J; Dallaire B; Sisk R; Gyves J
Invest New Drugs; 1993 Feb; 11(1):61-5. PubMed ID: 8349438
[TBL] [Abstract][Full Text] [Related]
2. Multicenter phase II trial of brequinar sodium in patients with advanced melanoma.
Natale R; Wheeler R; Moore M; Dallaire B; Lynch W; Carlson R; Grillo-Lopez A; Gyves J
Ann Oncol; 1992 Sep; 3(8):659-60. PubMed ID: 1450049
[TBL] [Abstract][Full Text] [Related]
3. Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck.
Urba S; Doroshow J; Cripps C; Robert F; Velez-Garcia E; Dallaire B; Adams D; Carlson R; Grillo-Lopez A; Gyves J
Cancer Chemother Pharmacol; 1992; 31(2):167-9. PubMed ID: 1451236
[TBL] [Abstract][Full Text] [Related]
4. Multicenter phase II study of brequinar sodium in patients with advanced lung cancer.
Maroun J; Ruckdeschel J; Natale R; Morgan R; Dallaire B; Sisk R; Gyves J
Cancer Chemother Pharmacol; 1993; 32(1):64-6. PubMed ID: 8384937
[TBL] [Abstract][Full Text] [Related]
5. Multicenter phase II study of brequinar sodium in patients with advanced breast cancer.
Cody R; Stewart D; DeForni M; Moore M; Dallaire B; Azarnia N; Gyves J
Am J Clin Oncol; 1993 Dec; 16(6):526-8. PubMed ID: 8256771
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
[TBL] [Abstract][Full Text] [Related]
7. Marimastat. BB 2516, TA 2516.
Drugs R D; 1999 Feb; 1(2):146-9. PubMed ID: 10566011
[No Abstract] [Full Text] [Related]
8. Phase I and pharmacokinetic study of brequinar (DUP 785; NSC 368390) in cancer patients.
de Forni M; Chabot GG; Armand JP; Fontana X; Recondo G; Domenge C; Carde P; Barbu M; Gouyette A
Eur J Cancer; 1993; 29A(7):983-8. PubMed ID: 8499153
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial with Brequinar (DUP-785, NSC 368390) in patients with metastatic colorectal cancer: a study of the Early Clinical Trials Group of the EORTC.
Dodion PF; Wagener T; Stoter G; Drozd A; Lev LM; Skovsgaard T; Renard J; Cavalli F
Ann Oncol; 1990; 1(1):79-80. PubMed ID: 2078489
[No Abstract] [Full Text] [Related]
10. EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group.
Dirix LY; Tonnesen F; Cassidy J; Epelbaum R; ten Bokkel Huinink WW; Pavlidis N; Sorio R; Gamucci T; Wolff I; Te Velde A; Lan J; Verweij J
Eur J Cancer; 1996 Oct; 32A(11):2019-22. PubMed ID: 8943690
[TBL] [Abstract][Full Text] [Related]
11. A phase I clinical and pharmacokinetic study of Brequinar sodium, DUP 785 (NSC 368390), using a weekly and a biweekly schedule.
Bork E; Vest S; Hansen HH
Eur J Cancer Clin Oncol; 1989 Oct; 25(10):1403-11. PubMed ID: 2591433
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel delivers new management opportunities for gastrointestinal carcinomas.
Rougier P
Anticancer Drugs; 1995 Jul; 6 Suppl 4():25-9. PubMed ID: 8745351
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies.
Schwartsmann G; Dodion P; Vermorken JB; ten Bokkel Huinink WW; Joggi J; Winograd B; Gall H; Simonetti G; van der Vijgh WJ; van Hennik MB
Cancer Chemother Pharmacol; 1990; 25(5):345-51. PubMed ID: 2306795
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).
Noe DA; Rowinsky EK; Shen HS; Clarke BV; Grochow LB; McGuire WB; Hantel A; Adams DB; Abeloff MD; Ettinger DS
Cancer Res; 1990 Aug; 50(15):4595-9. PubMed ID: 2369734
[TBL] [Abstract][Full Text] [Related]
15. Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer.
Hubbard KP; Pazdur R; Ajani JA; Braud E; Blaustein A; King M; Llenado-Lee M; Winn R; Levin B; Abbruzzese JL
Am J Clin Oncol; 1992 Dec; 15(6):524-7. PubMed ID: 1449117
[TBL] [Abstract][Full Text] [Related]
16. Oral carmofur in advanced gastrointestinal cancer.
Gröhn P; Heinonen E; Kumpulainen E; Länsimies H; Lantto A; Salmi R; Pyrhönen S; Numminen S
Am J Clin Oncol; 1990 Dec; 13(6):477-9. PubMed ID: 2239802
[TBL] [Abstract][Full Text] [Related]
17. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
[TBL] [Abstract][Full Text] [Related]
18. High-dose infusional 5-fluorouracil combination therapy of metastatic gastric and colorectal cancer.
Loeffler TM; Hausamen TU
J Infus Chemother; 1996; 6(3):137-40. PubMed ID: 9229325
[TBL] [Abstract][Full Text] [Related]
19. Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas. A phase II study of the Northern California Oncology Group.
Carlson RW; Doroshow JH; Odujinrin OO; Flam MS; Malec M; Lamborn KR
Invest New Drugs; 1990 Nov; 8(4):387-9. PubMed ID: 2150672
[No Abstract] [Full Text] [Related]
20. Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract.
Wadler S; Damle S; Haynes H; Kaleya R; Schechner R; Berkenblit R; Ladner RD; Murgo A
J Clin Oncol; 1999 Jun; 17(6):1771-8. PubMed ID: 10561214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
